Novartis Ag Stock Total Asset
NVSEF Stock | USD 95.11 4.87 5.40% |
Novartis AG fundamentals help investors to digest information that contributes to Novartis' financial success or failures. It also enables traders to predict the movement of Novartis Pink Sheet. The fundamental analysis module provides a way to measure Novartis' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Novartis pink sheet.
Novartis |
Novartis AG Company Total Asset Analysis
Novartis' Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Novartis Total Asset | 117.45 B |
Most of Novartis' fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novartis AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
Competition |
Based on the latest financial disclosure, Novartis AG has a Total Asset of 117.45 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The total asset for all United States stocks is significantly lower than that of the firm.
Novartis Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novartis' direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Novartis could also be used in its relative valuation, which is a method of valuing Novartis by comparing valuation metrics of similar companies.Novartis is currently under evaluation in total asset category among related companies.
Novartis Fundamentals
Return On Equity | 0.11 | |||
Return On Asset | 0.0645 | |||
Profit Margin | 0.13 % | |||
Operating Margin | 0.25 % | |||
Current Valuation | 207.39 B | |||
Shares Outstanding | 2.12 B | |||
Shares Owned By Insiders | 3.74 % | |||
Shares Owned By Institutions | 33.74 % | |||
Price To Earning | 25.00 X | |||
Price To Book | 3.22 X | |||
Price To Sales | 3.82 X | |||
Revenue | 51.83 B | |||
Gross Profit | 36.74 B | |||
EBITDA | 16.39 B | |||
Net Income | 6.96 B | |||
Cash And Equivalents | 19.1 B | |||
Cash Per Share | 8.81 X | |||
Total Debt | 20.24 B | |||
Debt To Equity | 0.47 % | |||
Current Ratio | 1.31 X | |||
Book Value Per Share | 28.00 X | |||
Cash Flow From Operations | 14.24 B | |||
Earnings Per Share | 3.17 X | |||
Price To Earnings To Growth | 5.67 X | |||
Number Of Employees | 102 K | |||
Beta | 0.47 | |||
Market Capitalization | 183.29 B | |||
Total Asset | 117.45 B | |||
Working Capital | 1.28 B | |||
Current Asset | 25.88 B | |||
Current Liabilities | 24.6 B | |||
Z Score | 5.4 | |||
Annual Yield | 0.04 % | |||
Five Year Return | 3.29 % | |||
Net Asset | 117.45 B | |||
Last Dividend Paid | 3.46 |
About Novartis Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Novartis AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novartis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novartis AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Novartis in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Novartis' short interest history, or implied volatility extrapolated from Novartis options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novartis AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. Note that the Novartis AG information on this page should be used as a complementary analysis to other Novartis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Complementary Tools for Novartis Pink Sheet analysis
When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Transaction History View history of all your transactions and understand their impact on performance | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Stocks Directory Find actively traded stocks across global markets |